-transparent.png){kind=logo}
The combination of 8-methoxypsoralen (8-MOP) plus ultraviolet A light (320-400 nm), termed PUVA, is used in the treatment of psoriasis, a hyperproliferative disease of the skin. This treatment results in the formation of specific 8-MOP adducts with cellular DNA. We have previously developed monoclonal antibodies which recognize these 8-MOP photoadducts. We now report the use of these antibodies in an indirect immunofluorescence technique to study human skin biopsies. Nuclei in 3 of 5 skin biopsies from psoriasis patients undergoing PUVA therapy were positive for adducts. The presence of adducts by immunofluorescence did not correlate with plasma levels of 8-MOP. Enzyme-linked immunosorbent assays, used to determine whether 8-MOP photoadducts could be detected in DNA isolated from the lymphocytes of psoriasis patients after PUVA therapy, were negative.
X Y Yang, and
F P Gasparro, and
V A DeLeo, and
R M Santella
April 1985,
Nucleic acids research,
X Y Yang, and
F P Gasparro, and
V A DeLeo, and
R M Santella
January 1978,
Acta dermato-venereologica,
X Y Yang, and
F P Gasparro, and
V A DeLeo, and
R M Santella
December 1984,
National Cancer Institute monograph,
X Y Yang, and
F P Gasparro, and
V A DeLeo, and
R M Santella
March 1985,
Clinical and experimental dermatology,
X Y Yang, and
F P Gasparro, and
V A DeLeo, and
R M Santella
October 1978,
Scandinavian journal of haematology,
X Y Yang, and
F P Gasparro, and
V A DeLeo, and
R M Santella
February 1979,
Irish journal of medical science,
X Y Yang, and
F P Gasparro, and
V A DeLeo, and
R M Santella
December 1979,
Irish journal of medical science,
X Y Yang, and
F P Gasparro, and
V A DeLeo, and
R M Santella
September 1976,
Ugeskrift for laeger,
X Y Yang, and
F P Gasparro, and
V A DeLeo, and
R M Santella
March 1983,
Cancer letters,
X Y Yang, and
F P Gasparro, and
V A DeLeo, and
R M Santella
April 1958,
Science (New York, N.Y.),
